about
Dendritic-Tumor Fusion Cell-Based Cancer VaccinesA novel cancer vaccine strategy based on HLA-A*0201 matched allogeneic plasmacytoid dendritic cells.Systemic distribution and tumor localization of adoptively transferred lymphocytes in mice: comparison with physiologically based pharmacokinetic model.Adoptive T cell immunotherapy for cancer.MPGES-1-derived PGE2 suppresses CD80 expression on tumor-associated phagocytes to inhibit anti-tumor immune responses in breast cancer.Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cellsA therapeutic cancer vaccine against GL261 murine glioma.Exploiting beneficial alloreactive T cells.Redirecting adaptive immunity against foreign antigens to tumors for cancer therapy.Potential of tumour cells for delivering oncolytic viruses.Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines.Human dendritic cell line models for DC differentiation and clinical DC vaccination studies.Cell fusion: from hybridoma to dendritic cell-based vaccine.Restoration of Immune Responsiveness to Glioma by Vaccination of Mice with Established Brain Gliomas with a Semi-Allogeneic Vaccine.Combined alloreactive CTL cellular therapy with prodrug activator gene therapy in a model of breast cancer metastatic to the brainCancer vaccine by fusions of dendritic and cancer cells.Cancer immunotherapy by fusions of dendritic cells and tumor cells.The impact of dendritic cell-tumor fusion cells on cancer vaccines - past progress and future strategies.Semi-allogeneic vaccine for T-cell lymphoma.Preclinical development of hybrid cell vaccines for multiple myeloma.Immunotherapy of murine prostate cancer using whole tumour cells killed ex vivo by cytosine deaminase/5-fluorocytosine suicide-gene therapy.A limited autoimmunity to p185neu elicited by DNA and allogeneic cell vaccine hampers the progression of preneoplastic lesions in HER-2/NEU transgenic mice.Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.Magnetic resonance enterography for assessment of intestinal graft-versus-host disease after allogeneic stem cell transplantation.Induction of tolerance and immunity by redirected B cell-specific cytolytic T lymphocytes.Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141(+)XCR1+ dendritic cells.Immunotherapy of murine prostate cancer using whole tumor cells killed ex vivo by herpes simplex viral thymidine kinase/ganciclovir suicide gene therapy.The avidity of tumor-specific T cells amplified by a plasmacytoid dendritic cell-based assay can predict the clinical evolution of melanoma patients.Generation of immunogenic dendritic cells from human embryonic stem cells without serum and feeder cells.Skin Allografting Activates Anti-tumor Immunity and Suppresses Growth of Colon Cancer in Mice.Therapeutic Immunization against Glioblastoma
P2860
Q26744827-8D7ACEDE-D55D-4483-A2A6-6CA4E2D2D4FAQ33573323-08B9626D-8431-4826-8190-A68127319C1FQ34775046-B8DD90F1-E9DE-45C3-93A8-E075292570FEQ35081485-64C07372-FD83-4E1E-8B96-3C7DDCED7C17Q35832981-BF189FBE-04E4-4665-B97A-FD430053CFC0Q36131252-86E9572C-317A-4F3E-B85C-E4366E20DFA4Q36428569-E7D9D410-0F8C-4A00-99D2-325A7C80B8B9Q36498418-DE264950-2EBB-43D7-B8E0-DB716F8B80C4Q36663422-A2FBA35F-04B7-49AE-A651-448B3A35758FQ37115398-20742DB3-27F0-48E3-A24C-777E293E5402Q37181792-155F688A-0371-4A62-80D5-3756FCF5D489Q37229552-FFD83CE1-29C4-4386-815E-FD7BEF27A600Q37259630-F4C4F666-DBFA-40C1-A8CC-5A9E3ADBCF2EQ37286424-7A480BBE-FD9F-429D-B0D3-836A5B25AEFBQ37610904-73C1EEEC-D25C-4BE5-BE4D-868B257A5D0BQ37698219-675D7533-EB7C-4654-ABEF-B3FA9EC66ADCQ37773276-9CFFFF95-64A1-41F7-9F28-DE7D66667C1BQ38617733-F2E802A6-51F8-4AD8-9286-70080D170AA1Q40096668-F1780CF1-F5D4-4BA4-A0C9-291E94E09476Q40170765-AD3F0FA8-C84E-4E3F-8040-9477E721FDE9Q40422938-516E8A17-DB79-4532-BAE5-8216A713A669Q40423857-3C021003-87E1-42F8-BBB5-75F4EB00CBF7Q40491652-92173220-A641-434D-8C3C-39A25E7B33D5Q41652393-9272414C-B05A-4860-8C23-4B68DAF9FD40Q45871875-C50A5693-FD57-459F-821B-35CA07753808Q45874878-99C1C627-9256-4B28-A2AC-398FEF56B667Q45882341-BDB7A62D-56EA-44E0-A0F0-3043B9E5DFB5Q48351257-902FAA31-8B21-42F8-A848-9BF2C46F46F0Q53503551-E55396E4-4073-4AA0-BF04-D8C6509E5F2AQ55717021-836B31B5-48F6-4840-8004-0CDF49AC5578Q58700123-A184FF7B-4927-4CE2-9922-7CD9C9DF1398
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The allogeneic response and tumor immunity.
@ast
The allogeneic response and tumor immunity.
@en
The allogeneic response and tumor immunity.
@nl
type
label
The allogeneic response and tumor immunity.
@ast
The allogeneic response and tumor immunity.
@en
The allogeneic response and tumor immunity.
@nl
prefLabel
The allogeneic response and tumor immunity.
@ast
The allogeneic response and tumor immunity.
@en
The allogeneic response and tumor immunity.
@nl
P356
P1433
P1476
The allogeneic response and tumor immunity.
@en
P2093
P2888
P304
P356
10.1038/89008
P407
P577
2001-06-01T00:00:00Z